Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 39Thoracic 4Plasma cell 4Other neoplasm 3Other hematologic neoplasm 3Lymphoid 3Dermatologic 3Gynecologic 2Genitourinary 2Breast 1

Conditions

Prostatic Neoplasms 3Anemia 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Fatigue 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Critical Illness 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Epoetin Alfa 2Darbepoetin alfa 2venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1peginesatide 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1hematide 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1cabozantinib 1cabazitaxel 1bicalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anemia × Darbepoetin alfa × Genitourinary × Clear all
NCT00381836 2015-12-04

Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

University of Aarhus

Phase 2/3 Terminated
140 enrolled
Classical hematologyGenitourinary

Anemia, Fatigue, Neoplasms, Prostatic Neoplasms, Critical Illness

NCT00245895 2007-11-29

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

University of Washington

Phase 2 Completed
20 enrolled
Classical hematologyGenitourinary

Anemia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡